First Republic Investment Management, Inc. Tyme Technologies, Inc. Transaction History

First Republic Investment Management, Inc.

  • $34.7 Billion
  • Q3 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 13, 2020
SELL
$0.97 - $1.7 $77,600 - $136,000
-80,000 Closed
0 $0
Q1 2020

May 13, 2020
BUY
$0.9 - $1.95 $72,000 - $156,000
80,000 New
80,000 $88,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email